Genmab CEO points to Epkinly data as main event of the year

First-line therapy will possibly open a substantial market. Epkinly is currently accepted for DLBCL individuals that have actually gotten 2 or even more therapies.

发布者:BY MARKETWIRE,转转请注明出处:https://robotalks.cn/genmab-ceo-points-to-epkinly-data-as-main-event-of-the-year/

(0)
上一篇 1小时前
下一篇 1小时前

相关推荐

发表回复

您的邮箱地址不会被公开。 必填项已用 * 标注

联系我们

400-800-8888

在线咨询: QQ交谈

邮件:admin@example.com

工作时间:周一至周五,9:30-18:30,节假日休息

关注微信
社群的价值在于通过分享与互动,让想法产生更多想法,创新激发更多创新。